CJC-1295 vs Sermorelin
CJC-1295 and Sermorelin are both growth-hormone-releasing hormone (GHRH) analogs that act on the pituitary GHRH receptor. CJC-1295 without DAC, also called modified GRF 1-29, is described in research as a short-acting analog; lacking a drug affinity complex keeps its action brief, which research associates with preserving natural pulsatile growth hormone release. Its human evidence is early, drawn mainly from reviews, anti-doping detection work, and a small trial of the long-acting DAC form. Published reviews describe clinical use of Sermorelin in diagnosing and treating idiopathic growth hormone deficiency in children, and it continues to be discussed in research on adult-onset growth hormone insufficiency and other areas.
Key differences. In plain words.
- 01
Research on CJC-1295 without DAC emphasizes its short half-life and preservation of pulsatile growth hormone release, whereas published work on Sermorelin centers on its clinical use in pediatric growth hormone deficiency.
- 02
Sermorelin is classed as an approved analog with reviews describing clinical use in children with idiopathic growth hormone deficiency, while CJC-1295 is at an early-clinical stage with limited human data specific to the no-DAC form.
- 03
The main human trial evidence associated with CJC-1295 comes from a randomized controlled trial of the long-acting DAC form in healthy adults, while the no-DAC form appears mainly in reviews and anti-doping detection research.
- 04
Sermorelin research extends to exploratory work in recurrent glioma and to PEGylation of GHRH analogues, whereas CJC-1295 is discussed mainly in sports medicine, orthopaedic, and healthy-aging peptide reviews.
- 05
Research protocols have used 100–300 mcg per administration pre-sleep for CJC-1295 and 200–500 mcg per administration in the evening for Sermorelin, both 5 days per week in 12-week blocks with 4 weeks off.
Side by side. From the research.
Studied ranges describe what published research protocols have used. They are not instructions or recommendations. Products are sold for research purposes only; each order ships with a protocol guide for the specific product.
Mechanism
How it is thought to work
CJC-1295
Research describes it as a GHRH analog acting on pituitary receptors, with the absence of the drug affinity complex keeping its action brief rather than sustained.
GHRH Pathway
Studied as a releasing-hormone analog acting on the pituitary receptors that govern natural hormone pulses.
Short Half-Life
Without DAC its action is brief, which research associates with preserving the body's own pulsatile rhythm.
How it is thought to work
Sermorelin
Research investigates sermorelin for binding to the GHRH receptor on pituitary somatotrophs, studied for cAMP-mediated signaling that supports pulsatile growth-hormone release while leaving somatostatin feedback intact.
GHRH Receptor
Studied for activation of the pituitary GHRH receptor and the downstream cAMP and PKA signaling cascade.
Pulsatile Release
Explored for preserving the natural pulsatile pattern of growth-hormone secretion rather than a constant signal.
Feedback Intact
Studied as an upstream signal that remains subject to somatostatin and IGF-1 negative feedback.
Ask about CJC-1295 and Sermorelin
Plain answers from our library and the cited studies.
AI answers can be wrong. Research use only.

